Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy

ClinicalTrials.gov ID

NCT03542006

Lead Sponsor

Tel-Aviv Sourasky Medical CenterOTHER_GOV

Overall Status

Unknown status

Study Type

Interventional

Phase

Phase 2

Enrollment

35Estimated

Last Update Posted

May 31, 2018Actual

Start Date

Jun 1, 2018Estimated

Primary Completion Date

Jan 1, 2019Estimated

Completion Date

Apr 1, 2019Estimated

Official Title

Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy

Brief Summary

Examine the efficacy of brinzolamide for the treatment of central serous chorioretinopathy

Detailed Description

Brinzolamide is a carbonic anhydrase inhibitor. Previously, carbonic anhydrase inhibitors have been shown to be effective for the treatment of macular edema when administered orally, also for central serous chorioretinopathy. However, this treatment carries the risk of severe side effects.

The goal of this study is to examine the efficacy of the topical form of treatment of carbonic anhydrase inhibitors in patients with chronic, non-resolving, central serous chorioretinopathy.

• Central Serous Chorioretinopathy

• Brinzolamide Ophthalmic

Ages Eligible for Study

Adult (18-64)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Central serous chorioretinopathy (CSC) affecting the fovea, non-resolving after 4 months of follow-up
• Optical coherence tomography (OCT) shows foveal subretinal fluid
• Fluorescein angiography and indocyanine green confirm the diagnosis

Exclusion Criteria:

• Any other ophthalmic condition that may lead to subretinal fluid
• Choroidal neovascularization
• Myopia > -6D
• Previous treatment for CSC in the past 6 months
• Known allergy to fluorescein or indocyanin green
• Known allergy for brinzolamide
• Pregnancy, breast feeding

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Tel-Aviv Sourasky Medical CenterOTHER_GOV

+97226973408

• Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy

  NCT02153125

  Unknown statusInterventionalPhase 2Updated Jun 2, 2014
• A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

  NCT00326092

  CompletedInterventionalPhase 2Updated Nov 18, 2016
• Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections

  NCT04523844

  CompletedInterventionalNot ApplicableUpdated Aug 24, 2020
• 24-hr Intraocular Pressure Control With SIMBRINZA ®

  NCT02770248

  CompletedInterventionalPhase 4Updated Jul 2, 2018
• Eplerenone for Central Serous Chorioretinopathy

  NCT01822561

  CompletedInterventionalPhase 2Updated May 16, 2018
• Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination

  NCT00961649

  TerminatedInterventionalPhase 2Updated Jul 4, 2013